Tech Database: 2343 Vendors, 368 Product/Service categories, 4513 Products/Services

Search the Technology Database
Cordis 2.25 mm CYPHER Sirolimus-Eluting Stent Approved for Coronaries
Cordis Corp. offers the 2.25 mm CYPHER Sirolimus-Eluting Coronary Stent, which is indicated for treatment of coronary blockages in small vessels. Many types of patients...
Read More September 22, 2009
Product: CYPHER Sirolimus Company: Cordis Corp.
TAXUS Liberte Long Offers Stent Length of 38 mm
Boston Scientific's TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System is designed for long lesions. At 38 mm, it is the longest available DES, providing doctors...
Read More July 16, 2009
Product: Taxus Company: Boston Scientific
TAXUS Liberte Atom Coronary Stent Designed for 2.25 mm Vessels
Boston Scientific's TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System is a next-generation drug-eluting stent (DES) specifically designed for treating small...
Read More May 28, 2009
Product: TAXUS Express2 Atom Company: Boston Scientific
CYPHER Sirolimus-Eluting Stent Compares Well Against BMS at Six-Years
The CYPHER Sirolimus-eluting Coronary Stent offered by Cordis (a Johnson & Johnson company) was the first drug-eluting stent approved for the U.S. market when it was...
Read More March 5, 2009
Product: CYPHER Sirolimus Company: Cordis Corp.
Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease
Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native...
Read More February 10, 2009
Product: XIENCE V stent system Company: Abbott Vascular
Endeavor Sprint Drug-Eluting Stent Offered on Rapid Exchange System
The Endeavor Sprint drug-eluting stent (DES) is now offered on a rapid exchange (RX) delivery system. Using the Sprinter balloon catheter technology, the Endeavor Sprint...
Read More November 13, 2008
Product: Rapid Exchange Company: Medtronic, Inc.
TAXUS Atom DES Designed to Treat Tight Coronary Arteries
Boston Scientific's TAXUS Express2 Atom paclitaxel-eluting coronary stent system is a drug-eluting stent (DES) specifically designed for treating small coronary vessels....
Read More October 31, 2008
Product: TAXUS Express2 Atom Company: Boston Scientific
TAXUS Liberte DES Has Thinner Struts, More Flexibility
Boston Scientific Corp. offers its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System, which has substantially thinner struts and a more flexible cell...
Read More October 10, 2008
Product: TAXUS Liberte Company: Boston Scientific
Boston Scientific Features New Everolimus-Eluting Coronary Stent
The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System. Boston Scientific said the PROMUS Stent is highly deliverable, made...
Read More September 10, 2008
Product: PROMUS Company: Boston Scientific
Boston Scientific, Abbott Offer New Everolimus-Eluting Coronary Stents
The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System and Abbott Vascular’s XIENCE V Everolimus Eluting Coronary Stent...
Read More September 4, 2008
Product: PROMUS Company: Boston Scientific
Medtronic Starts U.S. Study Comparing Safety of Endeavor, Cypher Drug-Eluting Stents
Medtronic Inc. recently announced the initiation of the first investigational sites in the U.S. to participate in PROTECT, the company’s global study comparing the...
Read More August 26, 2008
Product: ENDEAVOR Company: Medtronic, Inc.
Stent Reportedly Accelerates Body’s Natural Healing Process
OrbusNeich will showcase its Genous Stent at TCT 2008, a stent that was CE Marked in 2005. The company’s data suggests that its R Stent has had better outcomes when...
Read More August 7, 2008
Product: Genous Company: OrbusNeich
XTENT Working to Bring Customizable Drug Eluting Stent Solution to CAD Patients
XTENT Inc.'s Custom NX stent system reportedly allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a...
Read More August 7, 2008
Product: Custom NX stent system Company: XTENT
Boston Scientific Offers PROMUS Everolimus-Eluting Coronary Stent System
Boston Scientific Corp. offers the PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is a private-labeled...
Read More July 3, 2008
Product: PROMUS Company: Boston Scientific
Endeavor Zotarolimus-Eluting Stent Offered for Treatment of Coronaries
Medtronic’s Endeavor Zotarolimus-Eluting Coronary Stent System is engineered for the treatment of coronary artery disease. Endeavor uses the Driver bare metal cobalt...
Read More May 13, 2008
Product: Endeavor Zotarolimus-Eluting Coronary Stent Company: Medtronic, Inc.
Sono-Tek Announces Peripheral Stent Coating System
June 20, 2007 — Sono-Tek Corporation recently announced the release of the MediCoat PSI, a system which offers the same cutting-edge precision stent coating features as...
Read More June 27, 2007
Product: MediCoat PSI Company: Sono-Tek Corp.
ACC2: SPIRIT III Proven Safe and Effective, Boston Scientific Announces
The results of Boston Scientific's pivotal SPIRIT III clinical trial reaffirmed prior safety and efficacy data for the market-leading TAXUS Express2 Paclitaxel-Eluting...
Read More March 28, 2007
Drug-Eluting Stent Features Hydrophilic Coating Technology
The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern...
Read More November 16, 2006
Product: CYPEHR SELECT Plus Stent Company: Cordis Corporation
FDA Approves Heart Stent Study
The FDA granted Conor Medsystems Inc. full approval to enroll up to 1,700 patients in its heart stent clinical trial. The study will test Conor’s CoStar heart stent...
Read More June 30, 2006
Product: CoStar Company: Conor Medsystems, Inc.
Stent Trials Show Low TLR, MACE Rates
The TAXUS Express2 is a stainless steel stent that uses Paclitaxel and Translute polymer to control the drug release. Clinical trials consistently show low TLR and MACE...
Read More June 30, 2006
Product: TAXUS Express2 Company: Boston Scientific
Stent Specifically Designed to Prevent Restenosis
Using a closed-cell design, the CYPHER stent delivers sirolimus, a drug that selectively targets and interrupts proliferating cells early in the cell cycle, halting the...
Read More June 30, 2006
Product: CYPHER Company: Cordis Corporation
Label Affirms No Increased Heart Attack Risk
The FDA has approved revised labeling for the instructions for use of the CYPHER Sirolimus-eluting Coronary Stent. The labeling now reflects FDA's review of clinical trial...
Read More June 29, 2006
Product: CYPHER Company: Cordis Corporation